Looking Ahead to 2025, this webinar will discuss how UK companies can get the most from key global life science business get togethers in 2025.
A panel of Expert serial conference attendees will discuss the evolving life science investment conference scene, how to get the most out of your time and budget in 2025 in San Francisco and beyond , share what to look out for, and top tips for first time and returning attendees alike.
We will discuss how best to engage with the week if you are going for the first time. We will reflect on how the development of London life science week is influencing decision makers thinking about how and where to spend tight budgets for 2025
On the webinar we will share details of the BIA event planned for the week and webinar attendees travelling to SF will gain access to our priority invite list.
Speakers:
Steve Bates OBE
What does your role at BIA involve?
Steve Bates is the CEO of the UK Bioindustry Association, the UK’s Trade Association for innovative life science companies with over 550 members. Steve is the visible face of the vibrant UK life sciences industry to government and media. He serves on the UK Government’s Life Sciences Council and the UK Biosecurity Leadership Council. Steve was a founder member of the UK Government’s Vaccine Taskforce in the Covid crisis, sitting on its steering Board alongside Kate Bingham. He is active member and former chair the International Council of Biotech Associations and has been a board member of EuropaBio since 2015.
Previous experience & achievements
Steve has championed, with government, effective industrial incentives like the Biomedical Catalyst, which have crowded in private sector investment into UK SMEs. He is a driving force behind the scale up agenda, spearheading policy agenda to unlock UK pension fund capital into productive UK growth in life sciences. He has forged several links for the sector across the USA, Europe and in China. In his time at the BIA, Steve has developed new member groups focused on cell and gene therapy, genomics and engineered biology. A strong advocate of partnership working, Steve champions sector collaboration with research charities and academia. Proud to lead an organisation with a diverse Board with over 40% female representation, Steve is committed to next generation talent and developing the skills needed for the sector to flourish. Before joining the BIA in 2012, Steve worked for Genzyme and was advisor to the UK Government of Tony Blair working on NHS reform and the Northern Ireland peace process. He was made OBE for services to innovation in 2017 and became a Fellow of the Academy of Medical Science in 2020.
Olivia Cavlan
Olivia Cavlan is a founding team member and Chief Corporate Development and Strategy Officer at Alchemab Therapeutics. Prior to Alchemab Olivia was an Investment Principal at SV Health Investors and a Partner with McKinsey & Company where she was part of the leadership team in the Healthcare Private Equity and Pharmaceutical practices. Alongside her role as a Non-Executive Director for the UK BioIndustry Association, Olivia is a member of the Investment Committee for Cancer Research UK’s (CRUK) Seed fund. She also co-founded and sits on the Board of Directors of Sevenless Therapeutics, a small molecule pain company. Olivia is a medic originally, holding an MBChB in Medicine and a BSc in Pharmacology from Bristol University.
BIA Annual Supporters
